Advertisement

Psychopharmacology

, Volume 47, Issue 1, pp 29–32 | Cite as

Dimethyltryptamine levels in blood of schizophrenic patients and control subjects

  • B. Angrist
  • S. Gershon
  • G. Sathananthan
  • R. W. Walker
  • B. Lopez-Ramos
  • L. R. Mandel
  • W. J. A. Vandenheuvel
Human Pharmacology

Abstract

A gas chromatographic-mass spectrometric determination of blood N,N-dimethyltryptamine in normal controls and schizophrenic patients was carried out with a sensitivity limit of 0.05 ng/ml whole blood. Although the results appear to suggest that the mean DMT level was higher in the total patient group, those patients with acute psychosis, female patients and patients with suspiciousness scores on the BPRS of 4 or over, the differences were not statistically significant.

Key words

Dimethyltryptamine DMT Blood levels Schizophrenia Assay 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aghajanian, G. K., Foote, W. E., Sheard, M. H.: Action of psychotogenic drugs in single raphe neurons. J. Pharmacol. exp. Ther. 171, 178–187 (1970)Google Scholar
  2. Bidder, T. G., Mandel, L. R., Ahn, H. S., Walker, R. W., Vanden-Heuvel, W. J. A.: Blood and urinary dimethyltryptamine concentrations in acute psychotic disorders. Lancet 1974I, 165Google Scholar
  3. Forrest, F. M., Forrest, Irene S., Mason, A. S.: Review of rapid urine tests for phenothiazine and related drugs. Amer. J. Psychiat. 118, 300–307 (1961)Google Scholar
  4. Lipinski, J. F., Mandel, L. R., Ahn, H. S., VandenHeuvel, W. J. A., Walker, R. W.: Blood dimethyltryptamine concentrations in psychotic disorders. Biol. Psychiat. 9, 89–91 (1974)Google Scholar
  5. Mandel, L. R.: Dimethyltryptamine: Its biosynthesis and possible role in mental disease. In: Neurotransmitter balance and behavior, E. F. Domino and J. Davis, eds., Ann Arbor, Michigan: Edward Brothers (in press, 1976)Google Scholar
  6. Walker, R. W., Ahn, H. S., Albers-Schonberg, G., Mandel, L. R., VandenHeuvel, W. J. A.: Gas chromatographic-mass spectrometric isotope dilution assay for N,N-dimethyltryptamine in human plasma. Biochem. Med. 8, 105–113 (1973)Google Scholar
  7. Wyatt, R. J., Gillin, J. C., Kaplan, J., Stillman, R., Mandel, L. R., Ahn, H. S., VandenHeuvel, W. J. A., Walker, R. W.: N,N-dimethyltryptamine: A possible relationship to schizophrenia. In: Advances in biochemical psychopharmacology, vol. II, pp. 299–313. New York: Raven Press 1974Google Scholar
  8. Wyatt, R. J., Mandel, L. R., Ahn, H. S., Walker, R. W., VandenHeuvel, W. J. A.: Gas chromatographic-mass spectrometric isotope dilution on N,N-dimethyltryptamine concentrations in normals and psychiatric patients. Psychopharmacologia (Berl.) 31, 265–270 (1973)Google Scholar
  9. Wyatt, R. J., Murphy, D. L., Belmaker, R., Cohen, S., Connelly, C. H., Pollin, W.: Reduced monoamine oxidase activity in platelets: A possible genetic marker for vulnerability to schizophrenia. Science 179, 916–918 (1973)Google Scholar

Copyright information

© Springer-Verlag 1976

Authors and Affiliations

  • B. Angrist
    • 1
  • S. Gershon
    • 1
  • G. Sathananthan
    • 1
  • R. W. Walker
    • 2
  • B. Lopez-Ramos
    • 2
  • L. R. Mandel
    • 2
  • W. J. A. Vandenheuvel
    • 2
  1. 1.New York University Medical CenterNew YorkU.S.A.
  2. 2.Merck Sharp & Dohme Research LaboratoriesRahway

Personalised recommendations